Goldline Pharmaceutical IPO GMP Today & Subscription Status Day 2
Goldline Pharmaceutical IPO is witnessing positive investor participation on Day 2 of subscription. The SME IPO opened for bidding on May 12, 2026, and investors are closely monitoring the latest GMP trends and subscription figures ahead of closing.
The issue is listed on the BSE SME platform and has attracted attention due to its pharma sector presence and healthy grey market premium.
Latest GMP of Goldline Pharmaceutical IPO
According to current grey market activity, the GMP of Goldline Pharmaceutical IPO is hovering around ₹13 to ₹14. Based on the upper price band of ₹43, the estimated listing price may reach around ₹56 to ₹57.
The steady GMP trend indicates positive investor sentiment and expectations of decent listing gains.
Subscription Status of Goldline Pharmaceutical IPO Day 2
The IPO is receiving healthy bids from retail investors and non-institutional investors. Market experts believe the subscription momentum may improve further on the final day of bidding.
Retail investor participation has remained one of the major highlights of this SME IPO.
Goldline Pharmaceutical IPO Important Details
IPO Open Date: May 12, 2026
IPO Close Date: May 14, 2026
Listing Exchange: BSE SME
Price Band: ₹41 to ₹43 per share
Face Value: ₹10 per share
Issue Size: ₹11.61 Crore
Lot Size: 3000 Shares
Minimum Investment: ₹2.58 Lakh
Listing Date: May 19, 2026
About Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited operates in the pharmaceutical products and healthcare segment. The company offers pharmaceutical formulations and healthcare solutions across multiple categories.
The company plans to use IPO proceeds for business expansion, working capital requirements, and strengthening operational capabilities.
Goldline Pharmaceutical IPO Review
Several factors are supporting investor interest in this IPO:
- Positive GMP trend in grey market
- Growing pharmaceutical sector demand
- SME IPO market momentum
- Strong retail investor participation
- Expansion opportunities in healthcare business
However, investors should also consider SME IPO volatility and liquidity risks before investing.
Should You Apply for Goldline Pharmaceutical IPO?
Investors looking for SME IPO opportunities with possible listing gains are actively tracking Goldline Pharmaceutical IPO. Current GMP and market demand suggest positive short-term sentiment.
Long-term investors should evaluate the company’s financials, valuation, and future growth opportunities before making investment decisions.
Conclusion
Goldline Pharmaceutical IPO Day 2 subscription status and GMP trends continue to remain positive in the SME IPO market. Investors are now watching final subscription figures and expected listing performance closely.
Stay connected for the latest IPO GMP updates, allotment details, and listing gains analysis.
